TY - JOUR
T1 - Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis
T2 - Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
AU - Egeberg, Alexander
AU - Wu, Jashin J.
AU - Korman, Neil
AU - Solomon, James A.
AU - Goldblum, Orin
AU - Zhao, Fangyi
AU - Mallbris, Lotus
N1 - Funding Information:
Funding sources: Supported by Eli Lilly and Company.
Publisher Copyright:
© 2018 American Academy of Dermatology, Inc.
PY - 2018/7
Y1 - 2018/7
N2 - Background: The impact of ixekizumab treatment for psoriasis on cardiovascular-related parameters in patients is unknown. Objective: To investigate cardiovascular-related parameters in patients with psoriasis treated with ixekizumab. Methods: In phase 3 trials, patients with moderate-to-severe psoriasis were randomized and treated with placebo, ixekizumab, or etanercept during the induction period (weeks 0-12; UNCOVER-1, UNCOVER-2, and UNCOVER-3). At week 12, responders were rerandomized to receive placebo or ixekizumab through the maintenance period (weeks 12-60; UNCOVER-1 and UNCOVER-2). Laboratory measures (fasting lipid profiles, glucose level, or high-sensitivity C-reactive protein [hsCRP] level), weight, blood pressure, and electrocardiograms were obtained through 60 weeks. Results: Baseline parameters were within normal ranges with the exception of elevated triglyceride and hsCRP levels. After maintenance dosing, no significant changes were observed versus placebo for total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, triglyceride, apolipoprotein A1, apolipoprotein B, or fasting glucose levels or for systolic/diastolic blood pressure at 60 weeks. Importantly, low-density lipoprotein–to–high-density lipoprotein ratios remained stable during the induction and maintenance periods. HsCRP concentrations were significantly reduced versus placebo at 12 weeks and remained reduced at 60 weeks, although not significantly. Although transient changes were observed for some parameters during the induction period, these changes did not persist into the maintenance period. Limitations: A lack of echocardiogram evaluations. Conclusions: Ixekizumab had a neutral impact on cardiovascular-related parameters in patients with psoriasis.
AB - Background: The impact of ixekizumab treatment for psoriasis on cardiovascular-related parameters in patients is unknown. Objective: To investigate cardiovascular-related parameters in patients with psoriasis treated with ixekizumab. Methods: In phase 3 trials, patients with moderate-to-severe psoriasis were randomized and treated with placebo, ixekizumab, or etanercept during the induction period (weeks 0-12; UNCOVER-1, UNCOVER-2, and UNCOVER-3). At week 12, responders were rerandomized to receive placebo or ixekizumab through the maintenance period (weeks 12-60; UNCOVER-1 and UNCOVER-2). Laboratory measures (fasting lipid profiles, glucose level, or high-sensitivity C-reactive protein [hsCRP] level), weight, blood pressure, and electrocardiograms were obtained through 60 weeks. Results: Baseline parameters were within normal ranges with the exception of elevated triglyceride and hsCRP levels. After maintenance dosing, no significant changes were observed versus placebo for total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, triglyceride, apolipoprotein A1, apolipoprotein B, or fasting glucose levels or for systolic/diastolic blood pressure at 60 weeks. Importantly, low-density lipoprotein–to–high-density lipoprotein ratios remained stable during the induction and maintenance periods. HsCRP concentrations were significantly reduced versus placebo at 12 weeks and remained reduced at 60 weeks, although not significantly. Although transient changes were observed for some parameters during the induction period, these changes did not persist into the maintenance period. Limitations: A lack of echocardiogram evaluations. Conclusions: Ixekizumab had a neutral impact on cardiovascular-related parameters in patients with psoriasis.
KW - IL-17A
KW - UNCOVER
KW - cardiovascular
KW - cholesterol
KW - hsCRP
KW - ixekizumab
KW - psoriasis
UR - http://www.scopus.com/inward/record.url?scp=85047192514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047192514&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2018.02.074
DO - 10.1016/j.jaad.2018.02.074
M3 - Article
C2 - 29548945
AN - SCOPUS:85047192514
SN - 0190-9622
VL - 79
SP - 104-109.e8
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -